Last Updated: November 16, 2026

Details for Patent: 12,201,614

« Back to Dashboard


Which drugs does patent 12,201,614 protect, and when does it expire?

Patent 12,201,614 protects SOHONOS and is included in one NDA.

This patent has twenty-eight patent family members in eighteen countries.

Summary for Patent: 12,201,614
Title:Methods for treating heterotopic ossification
Abstract:The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Inventor(s):Clarissa Desjardins, Donna Roy GROGAN, Jeffrey Neal PACKMAN, Mark Harnett
Assignee: Clementia Pharmaceuticals Inc
Application Number:US18/758,242
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Scope, Claims, and US Patent Landscape for United States Drug Patent 12,201,614 (Palovarotene Dose-Titration Regimens for FOP Flare-Ups and Tolerance Management)

United States Patent 12,201,614 is a method-of-treatment patent that claims palovarotene oral dosing regimens for fibrodysplasia ossificans progressiva (FOP) that hinge on (i) flare-up status, (ii) fixed induction durations (28 days flare-up high dose; at least 56 days maintenance), and (iii) patient-specific down-titration after “tolerance problems” are determined. The claim set is structured around multiple weight bands and alternative dose-reduction pathways, creating a defensible perimeter around “lower-dose” alternatives and duration variants while preserving a core schedule.


What is the scope of US Patent 12,201,614 claims on palovarotene dose reduction in FOP?

Core claim concept (Claim 1):
The patent claims a method of reducing heterotopic ossification in an FOP subject using palovarotene with a flare-up dependent schedule and an explicit dose-reduction step when tolerance problems occur.

Claim 1 structure: flare-up dependent fixed schedule + tolerance-based titration

Claim 1 recites:

  1. Disease target: “reducing heterotopic ossification” in “a subject with fibrodysplasia ossificans progressiva.”
  2. Flare-up stratified dosing:
    • No flare-up symptom period: oral 5 mg palovarotene daily.
    • Flare-up symptom period (≥1 flare-up symptom): oral 20 mg daily for 28 days.
    • Post-flare period: oral 10 mg daily for at least 56 days.
  3. Tolerance trigger: “determining that the subject is experiencing tolerance problems.”
  4. Response: “reducing the dose of palovarotene administered.”

Claim 1 legal “hooks” that expand enforcement leverage

  • Status-based dosing: uses a clinical discriminator (“experiencing at least one flare-up symptom”).
  • Hard temporal windows: 28-day flare period and “at least 56 days” maintenance period.
  • Mechanism-like step without requiring a specific mechanism: “tolerance problems” is a practical trigger that drives dose reduction.
  • Open-ended tolerance response: Claim 1 requires “reducing the dose,” but dependent claims specify examples.

What dose schedules and time windows are explicitly claimed (5/20/10 mg; 28 days; ≥56 days)?

Claim 1 explicit regimen

  • Non-flare: 5 mg daily
  • Flare-up: 20 mg daily for 28 days
  • After flare: 10 mg daily for at least 56 days
  • Then: determine tolerance problems and reduce dose

Duration variants inside dependent claims

  • Claim 18: 10 mg amount daily for 84 days
  • Claim 19: 10 mg amount daily for 56 days
    These two claims narrow enforcement to specific maintenance durations, but they also provide a path to argue equivalence when defendants run longer than minimum “at least 56 days.”

Flare type definition (what counts as a flare-up symptom)

  • Claim 20: at least one flare-up symptom chosen from:
    • swelling
    • pain
    • erythema
    • warmth
    • stiffness
    • decreased range of motion

This list matters because it narrows “flare-up symptom” ambiguity and gives litigators a concrete claim construction anchor.


What formulations are covered by US 12,201,614 (and what is not claimed)?

Palovarotene form coverage

The claims consistently cover:

  • “palovarotene” or a pharmaceutically acceptable salt thereof
  • administration is explicitly oral

There is no independent claim language limiting:

  • to a specific salt identity,
  • to a specific dosage form (tablet vs capsule),
  • or to a specific manufacturing process.

What the claims do not appear to require (based on the claim language provided)

  • No required co-therapy
  • No required laboratory metrics (beyond “tolerance problems”)
  • No required adverse event category (though tolerance problems implicitly encompass tolerability failures)
  • No required titration interval frequency other than the regimen schedule

How do the dose-reduction sub-claims work (tolerance problems trigger step c)?

Claim 1 requires dose reduction after tolerance problems are determined. Dependent claims supply alternative dose reduction levels and specific dose schedules.

Reduction pathways listed in dependent claims

  • Claim 2: reduce 20 mg to 15 mg
  • Claim 3: reduce 10 mg to 7.5 mg
  • Claim 4: reduce both:
    • 20 mg to 15 mg and
    • 10 mg to 7.5 mg

Alternative tolerance-adjusted schedules (step (c) variants)

  • Claim 5 (step c variant):
    • non-flare: 5 mg remains
    • flare: 15 mg for 28 days
    • post-flare: 10 mg for at least 56 days
  • Claim 6 (step c variant):
    • non-flare: 4 mg
    • flare: 15 mg for 28 days
    • post-flare: 7.5 mg for at least 56 days
  • Claim 7 (step c variant):
    • non-flare: 5 mg
    • flare: 10 mg for 28 days
    • post-flare: 10 mg for at least 56 days

Practical enforcement consequence

The patent is not just about the “standard” flare regimen. It is also about how clinicians should titrate down when tolerability breaks down, using specific palovarotene dose levels and duration markers. This reduces the ability of a generic or competitor to avoid infringement by adopting a lower-dose strategy that still matches the claim-defined titration logic.


What weight-band dosing scopes are claimed (10–20 kg; 20–40 kg; 40–60 kg; >60 kg)?

The patent includes multiple independent weight-specific method claims (Claims 8, 12, 15) that rebase the flare and non-flare doses and then still impose the tolerance trigger and dose reduction.

Claim 8: 10 to 20 kg

  • Non-flare: 2.5 mg daily
  • Flare-up: 10 mg daily for 28 days
  • After flare: 5 mg daily for at least 56 days
  • Then: determine tolerance problems and reduce dose

Dependent dose reductions (Claim 9):
Examples include reducing:

  • 2.5 mg to 1 mg, or
  • 10 mg to 7.5 mg, or
  • 5 mg to 3 mg

Claim 12: 20 to 40 kg

  • Non-flare: 3 mg daily
  • Flare-up: 12.5 mg daily for 28 days
  • After flare: 6 mg daily for at least 56 days
  • Then: determine tolerance problems and reduce dose

Dependent dose reductions (Claim 13):
Examples include reducing:

  • 3 mg to 2.5 mg, or
  • 12.5 mg to 10 mg, or
  • 6 mg to 5 mg

Claim 15: 40 to 60 kg

  • Non-flare: 4 mg daily
  • Flare-up: 15 mg daily for 28 days
  • After flare: 7.5 mg daily for at least 56 days
  • Then: determine tolerance problems and reduce dose

Dependent dose reductions (Claim 16):
Examples include reducing:

  • 4 mg to 3 mg, or
  • 15 mg to 12.5 mg, or
  • 7.5 mg to 6 mg

Bodyweight >60 kg

  • Claim 21: “subject weighs greater than 60 kg” This claim language appears to define an additional population, but the provided text does not include an associated full dosing regimen in the portion you supplied. Enforcement coverage for >60 kg hinges on the remainder of the specification and other claims not provided in your excerpt.

Duration variants inside weight-band sections

For each weight-band claim, the patent includes duration variants:

  • Claim 22: Claim 8 non-flare dose (5 mg amount) for 84 days
  • Claim 23: Claim 8 non-flare dose (5 mg amount) for 56 days
  • Claim 25: Claim 12 post-flare dose (6 mg amount) for 84 days
  • Claim 26: Claim 12 post-flare dose (6 mg amount) for 56 days
  • Claim 28: Claim 15 post-flare dose (7.5 mg amount) for 84 days
  • Claim 29: Claim 15 post-flare dose (7.5 mg amount) for 56 days

These variants can materially affect litigation posture because defendants often deviate on maintenance duration while keeping dose levels close.


What flare-up symptoms are specified, and why does it matter for claim scope?

Across Claim 1 and the weight-band claims, “flare-up symptom” is anchored to a discrete symptom list:

  • swelling
  • pain
  • erythema
  • warmth
  • stiffness
  • decreased range of motion

This matters because a design-around could try to argue:

  • a particular clinician’s documentation does not match the symptom list, or
  • the timing of “flare-up period” is not aligned to the 28-day dosing window.

The symptom list creates an evidentiary roadmap for enforcement.


How broad is infringement risk across alternative titration regimens?

The claim set covers multiple concrete dose triplets and reduction levels.

Infringement risk is highest when defendants match all three elements

To fall within the provided claim language, accused methods must typically include:

  1. Palovarotene oral administration in an FOP subject
  2. Flare-up status driven dosing schedule with:
    • non-flare dose,
    • flare dose for 28 days,
    • post-flare maintenance at least 56 days
  3. Tolerance-based reduction after a determination of tolerance problems

Key design-around vectors and how the claims constrain them

  • Skipping “tolerance problems” determination: If no formal determination or if reduction is not tied to “tolerance problems,” a defendant may argue it is not “step (c).”
  • Changing the 28-day flare period: Claims explicitly anchor “for a period of 28 days.” Shorter or longer flare windows can reduce direct match.
  • Avoiding specific dose levels: Moving to dose levels not recited in dependent claims can reduce literal match, but Claim 1’s open-ended “reducing the dose” means any reduction step still needs to be within the claim’s dosing framework.
  • Replacing symptom-based flare criteria: Using different clinical criteria without using the claimed symptom list can attempt to avoid the “experiencing at least one flare-up symptom” requirement.

What is the patent landscape around US 12,201,614 for palovarotene in FOP (Orange Book, compendia, and related estates)?

No complete, reliable patent-landscape mapping is possible from the information provided. The dataset necessary to enumerate:

  • all Orange Book listed patents associated with the palovarotene NDA,
  • continuation or divisional families,
  • related US application numbers and publication counterparts,
  • expiration and pediatric exclusivity impact,
  • and any litigation (including Paragraph IV) tied to palovarotene is not included in your prompt.

The only artifact supported by your input is the claim text for US 12,201,614, which is sufficient for scope analysis but not for an authoritative landscape audit.

Therefore, no additional landscape assertions are provided here.


How strong is the claim estate based on claim drafting quality and redundancy?

Strength indicators from the claim structure

  • Multiple independent weight-band methods (Claims 8, 12, 15) increase enforcement footprint beyond the single baseline regimen.
  • Numerous dependent claims specify alternative titration reductions (15, 7.5, 10, 12.5, 10, 6, 3, 2.5, 1, 7.5 etc.). This creates overlap that reduces design-around space.
  • Explicit symptom list supports claim construction and documentation-based proof.
  • Duration variants (56 vs 84 days) create multiple “targetable” practice patterns.

Main weakness vector

  • The claims require the method to include tolerance determination and dose reduction. If a competing protocol uses alternative triggers (such as lab thresholds) or ties dose changes to different decision logic not characterized as “tolerance problems,” the patent may be harder to assert under strict claim matching.

Key Takeaways

  • US 12,201,614 claims oral palovarotene regimens for FOP with a flare-up dependent schedule and a tolerance-triggered dose reduction step.
  • The baseline regimen in Claim 1 is 5 mg daily (non-flare) / 20 mg daily for 28 days (flare) / 10 mg daily for at least 56 days (post-flare), followed by dose reduction after “tolerance problems.”
  • Dependent claims lock multiple down-titration levels (including 20→15 mg, 10→7.5 mg, and combinations) and provide alternative step-(c) schedules.
  • Independent claims cover weight bands 10–20 kg, 20–40 kg, and 40–60 kg with proportionate flare and maintenance doses, plus additional dependent claims for specific duration variants.
  • Enforcement is most practical where clinical practice documents flare timing and symptom presence consistent with the claimed symptom list and implements a tolerance-driven dose reduction matching the recited dose levels and durations.

FAQs

1) Does US 12,201,614 cover palovarotene salts?
Yes. The claims cover “palovarotene or a pharmaceutically acceptable salt thereof” administered orally.

2) What flare-up duration is required for the high-dose period?
The flare-up dosing is specified as 28 days in the provided claims.

3) What maintenance duration is required after the 28-day flare period?
The post-flare dosing is at least 56 days, with dependent claims specifying 56 days or 84 days for certain dose amounts.

4) What symptoms qualify as flare-up symptoms under the claims?
Swelling, pain, erythema, warmth, stiffness, and decreased range of motion.

5) Can a protocol avoid infringement by using a different dose-reduction trigger than “tolerance problems”?
The claims require a determination that the subject is experiencing “tolerance problems” and then a dose reduction. If clinical protocols do not make that determination or do not tie dose reduction to tolerance, literal match to step (c) is less likely under strict interpretation of the provided claim text.


References (APA)

  1. United States Patent 12,201,614. (Claim text provided in user prompt).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,201,614

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-001 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-002 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-003 Aug 16, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.